Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Has Average Price Target of $27.18

Key Points

• Analyst sentiment is mixed: 23 analysts give Tandem Diabetes Care a consensus “Hold” rating, with an average 12-month price target of $27.18.
• Third-quarter results beat expectations: Revenue rose 13.8% year over year to $283.7 million, while the per-share loss of $0.10 was narrower than analysts’ $0.25 estimate. Gross margin also improved, though the company remains loss-making.
• Tandem forecast 2026 sales of $1.065 billion to $1.085 billion and named Jeannette Bankes as its next CEO, with John Sheridan expected to retire at the end of 2026.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-three analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $27.18.

Several research analysts recently commented on TNDM shares. Oppenheimer reissued an "outperform" rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. William Blair initiated coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They issued an "outperform" rating for the company. Truist Financial cut their target price on Tandem Diabetes Care from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, September 24th. Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research report on Friday. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the firm's stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director directly owned 24,434 shares in the company, valued at $467,911.10. This trade represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.10% of the company's stock.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of large investors have recently added to or reduced their stakes in the business. Maryland State Retirement & Pension System acquired a new position in Tandem Diabetes Care in the third quarter worth about $249,000. Fulcrum Asset Management LLP lifted its holdings in shares of Tandem Diabetes Care by 1,463.6% during the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company's stock worth $73,000 after purchasing an additional 4,098 shares during the period. Provenance Wealth Advisors LLC purchased a new position in shares of Tandem Diabetes Care in the third quarter valued at $158,000. Summit Global Investments increased its holdings in shares of Tandem Diabetes Care by 13.9% during the third quarter. Summit Global Investments now owns 24,753 shares of the medical device company's stock valued at $404,000 after acquiring an additional 3,017 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Tandem Diabetes Care by 31.3% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,400 shares of the medical device company's stock worth $561,000 after purchasing an additional 8,200 shares during the period.

Tandem Diabetes Care News Roundup

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations of $265.85 million. The loss of $0.10 per share was also narrower than the consensus loss of roughly $0.25. Gross margin improved to 57%, up 2.7 percentage points year over year. Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Tandem forecast 2026 sales of $1.065 billion to $1.085 billion, providing investors with a full-year revenue outlook. Tandem outlines 2026 sales range as CEO transition is set
• Neutral Sentiment: Jeannette Bankes was named president and CEO, succeeding John Sheridan, who is expected to retire at the end of 2026. The planned handover offers continuity but adds a leadership transition for investors to monitor. Tandem names Jeannette Bankes CEO
• Neutral Sentiment: Analyst actions were mixed: Barclays raised its target from $18 to $20 but kept an Equal Weight rating, while Wells Fargo lowered its target from $27 to $25 and maintained Overweight. Both targets remain above the cited $16.91 share price. Barclays rating information Wells Fargo target revision
• Negative Sentiment: Despite improved results, Tandem remains loss-making, with a negative net margin. Continued losses could limit how much investors reward revenue and margin progress. Tandem reports third-quarter loss

Tandem Diabetes Care Trading Down 6.0%

Shares of NASDAQ TNDM opened at $16.91 on Friday. The company has a market cap of $1.18 billion, a PE ratio of -23.49 and a beta of 1.59. Tandem Diabetes Care has a 1-year low of $12.26 and a 1-year high of $29.65. The company has a current ratio of 3.18, a quick ratio of 2.65 and a debt-to-equity ratio of 4.62. The company has a 50-day moving average of $17.65 and a two-hundred day moving average of $18.88.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The firm had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. During the same period in the prior year, the business posted ($0.31) earnings per share. The company's quarterly revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts expect that Tandem Diabetes Care will post -0.66 earnings per share for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.